PDS Biotechnology Corp.
(NASDAQ : PDSB)

( )
PDSB PreMarket: $ () as of AM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Pharmaceuticals Major
symbolcompany%chnglast%shortavg$volume
ABBVAbbVie, Inc. 0.42%91.001.9%$1171.89m
JNJJohnson & Johnson 0.98%145.970.7%$1065.86m
BMYBristol-Myers Squibb Co. 0.23%60.461.0%$969.39m
MRKMerck & Co., Inc. 0.44%77.600.7%$838.04m
PFEPfizer Inc. 0.67%37.750.9%$837.20m
LLYEli Lilly & Co. 1.24%149.781.1%$429.04m
AZNAstraZeneca Plc -1.34%52.401.2%$250.76m
NVSNovartis AG -0.89%84.290.2%$155.38m
GSKGlaxoSmithKline Plc -0.27%40.630.2%$136.94m
NVONovo Nordisk A/S -0.82%62.880.1%$84.93m
SNYSanofi -1.21%46.700.2%$78.59m
RGENRepligen Corp. -4.42%133.357.1%$69.88m
ARCTArcturus Therapeutics Holdings, Inc. -6.81%54.300.0%$55.02m
BHVNBiohaven Pharmaceutical Holding Co. Ltd. 2.78%60.000.0%$45.76m
RETAReata Pharmaceuticals, Inc. -1.40%157.763.4%$37.79m

Company Profile

PDS Biotechnology Corp. engages in the development of clinical-stage immunotherapies to treat various early-stage and late-stage cancers, including head and neck cancer, prostate cancer, breast cancer, cervical cancer, anal cancer, and other cancers. Its products PDS0101, is an off the shelf immunotherapeutic that is administered by subcutaneous injection. The company was founded by Frank K. Bedu-Addo on March 15, 2019 and is headquartered in Princeton, NJ.